← Back to Screener
IO Biotech, Inc. Common Stock (IOBT)
Price$0.01
Favorite Metrics
Price vs S&P 500 (26W)-102.63%
Price vs S&P 500 (4W)-102.11%
Market Capitalization$554,006
All Metrics
Book Value / Share (Quarterly)$0.01
P/TBV (Annual)0.56x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.16
Price vs S&P 500 (YTD)-101.53%
EPS (TTM)$-1.34
10-Day Avg Trading Volume61.90M
EPS Excl Extra (TTM)$-1.34
EPS (Annual)$-1.98
ROI (Annual)-64.65%
Cash / Share (Quarterly)$0.44
ROA (Last FY)-57.12%
EBITD / Share (TTM)$-1.39
Cash Flow / Share (Annual)$-1.25
P/B Ratio0.61x
P/B Ratio (Quarterly)27.78x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-1694.25x
ROA (TTM)-180.56%
EPS Incl Extra (Annual)$-1.98
Current Ratio (Annual)3.33x
Quick Ratio (Quarterly)1.72x
3-Month Avg Trading Volume14.67M
52-Week Price Return-99.24%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.39
52-Week High$2.79
EPS Excl Extra (Annual)$-1.98
26-Week Price Return-98.64%
Quick Ratio (Annual)3.18x
13-Week Price Return-98.66%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.01x
Enterprise Value$-13.446
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.91
3-Month Return Std Dev449.91%
Net Income / Employee (TTM)$-1
ROE (Last FY)-64.65%
Net Interest Coverage (Annual)-7.29x
EPS Basic Excl Extra (Annual)$-1.98
Total Debt / Equity (Quarterly)18.29x
EPS Incl Extra (TTM)$-1.34
ROI (TTM)-355.80%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.82
Price vs S&P 500 (52W)-129.07%
Year-to-Date Return-98.88%
5-Day Price Return-44.72%
EPS Normalized (Annual)$-1.98
ROA (5Y Avg)-92.05%
Month-to-Date Return-88.42%
Cash Flow / Share (TTM)$-2.33
EBITD / Share (Annual)$-2.10
LT Debt / Equity (Quarterly)18.29x
EPS Basic Excl Extra (TTM)$-1.34
P/TBV (Quarterly)0.49x
P/B Ratio (Annual)1.29x
Book Value / Share (Annual)$0.71
Price vs S&P 500 (13W)-99.34%
Beta0.38x
Revenue / Share (TTM)$0.00
ROE (TTM)-465.36%
52-Week Low$0.01
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.83
2.60
2.60
2.50
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IOBTIO Biotech, Inc. Common Stock | — | — | — | — | $0.01 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
IO Biotech is a clinical-stage biopharmaceutical company developing cancer vaccines using its proprietary T-win technology platform. The company's approach targets multiple immunosuppressive pathways to enhance the immune system's ability to recognize and attack cancer cells. This dual-pathway targeting strategy aims to overcome a key mechanism by which tumors evade immune response.